Contact this trialFirst, we need to learn more about you.
Antibody-Drug Conjugate
Enfortumab Vedotin + Pembrolizumab for Testicular and Urinary Tract Cancer
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is testing a combination of two drugs, enfortumab vedotin and pembrolizumab, in adults with rare testicle or urinary tract cancers. Enfortumab vedotin targets and kills cancer cells, while pembrolizumab boosts the immune system to fight the cancer. The goal is to see if this combination can help patients who have not responded to other treatments.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service